Basic information Safety Supplier Related

AZD-5672

Basic information Safety Supplier Related

AZD-5672 Basic information

Product Name:
AZD-5672
Synonyms:
  • AZD-5672
  • UNII-61XQN688TW
  • Benzeneacetamide, N-[1-[(3R)-3-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]propyl]-4-piperidinyl]-N-ethyl-4-(methylsulfonyl)-
  • N-{1-[(3R)-3-(3,5-difluorophenyl)-3-(4-methanesulfonylphenyl)propyl]piperidin-4-yl}-N-ethyl-2-(4-methanesulfonylphenyl)acetamide
  • AZD-5672, 10 mM in DMSO
CAS:
780750-65-4
MF:
C32H38F2N2O5S2
MW:
632.78
Mol File:
780750-65-4.mol
More
Less

AZD-5672 Chemical Properties

Boiling point:
800.4±65.0 °C(Predicted)
Density 
1.33±0.1 g/cm3(Predicted)
storage temp. 
Store at -20°C
form 
Solid
pka
8.54±0.20(Predicted)
color 
White to light brown
More
Less

AZD-5672 Usage And Synthesis

Uses

AZD-5672 is an orally active, potent, and selective CCR5 antagonist (IC50=0.32 nM). AZD-5672 shows moderate activity against the hERG ion channel (binding IC50=7.3 μM). AZD5672 is a substrate of human P-gp, and inhibits P-gp-mediated digoxin transport (IC50=32 μM). AZD-5672 can be used for the research of rheumatoid arthritis[1][2][3].

in vivo

In vivo pharmaeokineties data for AZD-5672 (compound 1)[1]

SpeciesCIa
(mL/min/kg)
Vssa (L/kg)t1/2a (h)Fb (%)
Rat285.32.638
Dog185.73.986

a AZD-5672 dosed 1-2 mg/kg i.v.
b AZD-5672 dosed 2-5 mg/kg p.o.

IC 50

CCR5: 0.32 nM (IC50); hERG: 7.3 μM (IC50); hP-gp: 32 μM (IC50)

References

[1] Cumming JG, et al. Balancing hERG affinity and absorption in the discovery of AZD5672, an orally active CCR5 antagonist for the treatment of rheumatoid arthritis. Bioorg Med Chem Lett. 2012 Feb 15;22(4):1655-9. DOI:10.1016/j.bmcl.2011.12.117
[2] Elsby R, et al. The utility of in vitro data in making accurate predictions of human P-glycoprotein-mediated drug-drug interactions: a case study for AZD5672. Drug Metab Dispos. 2011 Feb;39(2):275-82. DOI:10.1124/dmd.110.035881
[3] Gerlag DM, et al. Preclinical and clinical investigation of a CCR5 antagonist, AZD5672, in patients with rheumatoid arthritis receiving methotrexate. Arthritis Rheum. 2010 Nov;62(11):3154-60. DOI:10.1002/art.27652

AZD-5672Supplier

BOC Sciences
Tel
1-631-485-4226; 16314854226
Email
info@bocsci.com
ShangHai Caerulum Pharma Discovery Co., Ltd.
Tel
18149758185
Email
sales-cpd@caerulumpharma.com
Shanghai Lollane Biological Technology Co.,Ltd.
Tel
021-52996696,15000506266 15000506266
ShangHai Biochempartner Co.,Ltd
Tel
177-54423994 17754423994
Email
2853530910@QQ.com
TargetMol Chemicals Inc.
Tel
+1-781-999-5354; +17819995354
Email
marketing@targetmol.com